Mark Munch - Bruker President of Bruker Nano Group
| BRKR Stock | USD 58.90 1.83 3.21% |
President
Dr. Mark R. Munch, Ph.D., is Executive Vice President President of Bruker Nano Group and Bruker Nano Surfaces Division of the Company. Dr. Munch has served since September 2012 as President, Bruker Nano Group, with responsibility for management of the global operations of our Bruker Nano Group, which manufactures and distributes the Company advanced analytical Xray technologies and sparkoptical emission spectroscopy, atomic force microscopy, fluorescence microscopy, and stylus and optical metrology instrumentation used in nondestructive molecular, materials and elemental analysis. He has also served, since July 2015, as an Executive Vice President of the Company, and in that capacity is responsible for providing oversight to the Company global information technology function and enterprise resource planning, as well as other strategic management development and business process initiatives. Dr. Munch has also served as President of Bruker Nano, Inc., a whollyowned subsidiary of the Company, since October 2010. Prior to joining Bruker Nano, Inc., from February 2008 to October 2010, Dr. Munch was Executive Vice President of Veeco Instruments Inc. Dr. Munch also served as a Senior Vice President of Coherent, Inc. from February 2006 to January 2008 and as President and Chief Executive Officer of Cooligy, Inc., a subsidiary of Emerson Electric, from 2004 to 2006. Dr. Munch background includes over 26 years of experience in marketing, product development, operations and sales, as well as experience in managing significant business units of multinational corporations since 2015.
| Age | 62 |
| Tenure | 9 years |
| Address | 40 Manning Road, Billerica, MA, United States, 01821 |
| Phone | 978 663 3660 |
| Web | https://www.bruker.com |
Bruker Management Efficiency
The company has return on total asset (ROA) of 0.0483 % which means that it generated a profit of $0.0483 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1973 %, meaning that it created $0.1973 on every $100 dollars invested by stockholders. Bruker's management efficiency ratios could be used to measure how well Bruker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 11/26/2024, Return On Assets is likely to grow to 0.11, while Return On Capital Employed is likely to drop 0.09. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 11/26/2024, Intangibles To Total Assets is likely to grow to 0.23, while Intangible Assets are likely to drop slightly above 196.5 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Alex Thurman | Glaukos Corp | 54 | |
| Stephanie Bolton | LivaNova PLC | 42 | |
| Kirk Thor | Integer Holdings Corp | 60 | |
| Joel Becker | Integer Holdings Corp | 53 | |
| Annette Tumolo | Bio Rad Laboratories | 65 | |
| David Murray | CONMED | 76 | |
| Peter Shagory | CONMED | 55 | |
| Payman Khales | Integer Holdings Corp | 54 | |
| David Bailey | Orthopediatrics Corp | 45 | |
| Gregg Sutton | SurModics | 64 | |
| Johonna Pelletier | CONMED | 51 | |
| Jon Serbousek | Orthofix Medical | 63 | |
| Gregory Odle | Orthopediatrics Corp | 54 | |
| Michael Crowley | Bio Rad Laboratories | 62 | |
| Derek Davis | Zimmer Biomet Holdings | 51 | |
| Ronald Hutton | Bio Rad Laboratories | 62 | |
| Mark Day | iRhythm Technologies | 53 | |
| Keyna Skeffington | LivaNova PLC | 61 | |
| Erick DeVinney | Axogen Inc | 48 | |
| Kimberley Elting | Orthofix Medical | 59 | |
| Heather Cohen | CONMED | 51 | |
Management Performance
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0483 |
Bruker Leadership Team
Elected by the shareholders, the Bruker's board of directors comprises two types of representatives: Bruker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bruker. The board's role is to monitor Bruker's management team and ensure that shareholders' interests are well served. Bruker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bruker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Laukien, Chairman, CEO and Pres | ||
| Burkhard Prause, President and CEO, BEST | ||
| Collin DSilva, Pres Division | ||
| Gerald Herman, Interim CFO, Principal Accounting Officer | ||
| Gerald CPA, Executive CFO | ||
| Juergen Srega, President of Bruker Daltonics Division and President of Bruker Calid Group | ||
| Falko Busse, President of the Bruker BioSpin Group and Executive Officer of the Company | ||
| Urban Faeh, Pres GmbH | ||
| Justin Ward, Senior Development | ||
| Stacey Desrochers, Treasurer Relations | ||
| Mark Munch, President of Bruker Nano Group | ||
| Brent JD, General Secretary |
Bruker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bruker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0483 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 10.92 B | ||||
| Shares Outstanding | 151.6 M | ||||
| Shares Owned By Insiders | 31.91 % | ||||
| Shares Owned By Institutions | 79.71 % | ||||
| Number Of Shares Shorted | 3.81 M | ||||
| Price To Earning | 67.10 X |
Pair Trading with Bruker
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bruker position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bruker will appreciate offsetting losses from the drop in the long position's value.Moving together with Bruker Stock
Moving against Bruker Stock
| 0.81 | EXEL | Exelixis | PairCorr |
| 0.75 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.56 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.45 | KTTAW | Pasithea Therapeutics | PairCorr |
The ability to find closely correlated positions to Bruker could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bruker when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bruker - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bruker to buy it.
The correlation of Bruker is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bruker moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bruker moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bruker can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Bruker Stock Analysis
When running Bruker's price analysis, check to measure Bruker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bruker is operating at the current time. Most of Bruker's value examination focuses on studying past and present price action to predict the probability of Bruker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bruker's price. Additionally, you may evaluate how the addition of Bruker to your portfolios can decrease your overall portfolio volatility.